Q1 FY27 quarterly results (April-June 2026)

3,829 companies have declared Q1 FY27 results so far, the latest on 13 Oct 2026.

Across the 3,462 non-financial companies with a year-ago quarter to compare, sales grew +18.6% and net profit +4.4% year on year, and the combined operating margin narrowed 379 bps to 10.7%.

For the 109 banks and lenders, net interest income grew +11.8% and net profit +19.9%.

64% of companies grew net profit; 309 turned a loss into a profit; 43% beat their own profit trend and 40% fell short of it.

Updated 14 Oct 2026, 17:28 IST 3829 declared
The next results season has started: 50 companies have filed results for the quarter ended 30 Sep 2026. See them →

Q1 FY27 scoreboard

Sales growth
+18.6%
YoY, 3462 companies combined; median +15.3%
Net profit growth
+4.4%
YoY combined; median +20.7%
Operating margin
10.7%
-379 bps YoY
Grew profit
64%
309 turnarounds, 216 into loss
Vs own profit trend
43% / 40%
above / below, 17% in line
Banks: NII growth
+11.8%
109 lenders; profit +19.9%
Price since results
-3.9%
median; 39% of 3402 stocks up
Vs management guidance
2 / 1
ahead / behind of 3 with guidance
Other-income heavy
1059
25%+ of pre-tax profit from other income & one-offs

2 matching results 2

Glass Wall Systems (India) Limited

GLASSWALL · Construction & Infrastructure · Q1 FY27 · Consolidated · Filed
M Cap
₹2,218 Cr
P/E
—
PEG
—
Since results
-9.4%
  • Operating margin contracted 523 bps YoY
  • Ahead of management's FY27 revenue growth guidance of about 25% (Q1 FY27 +36.0%)
  • Behind management's FY27 EBITDA margin guidance of 23–25% (Q1 FY27 21.3%)
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +36.0%-9.7% 10711979.0
Operating profit +9.2%-11.8% 22.926.021.0
OPM % -523 bps-50 bps 21.3%21.8%26.6%
Other income -50.1%-50.1% 2.55.05.0
Net profit? -9.0%-17.6% 17.321.019.0
PAT margin % -795 bps-155 bps 16.1%17.6%24.1%
EPS (₹) -17.4%-17.1% 2.042.462.47

Quality of profit

Core 89%Other income & one-offs 11%

Pre-tax profit ₹23.1 Cr: core business ₹20.6 Cr, other income ₹2.5 Cr.

Core profit YoY: +2.8% · reported profit -9.0%

Management guidance ?

GuidedSo far
FY27 revenue growth about 25% +36.0% Q1 FY27
ahead
FY27 EBITDA margin 23–25% 21.3% Q1 FY27
behind
FY27 PAT margin 18–20% 16.1% Q1 FY27
behind
What management said
  • FY27 revenue growth: “In FY27, we have said this earlier with all our meetings, we are expecting around 25% growth on revenue, and EBITDA margins will be historically in the same range that we have delivered over the past 2 years, where EBITDAs are what we are aiming to deliver is around 23% to 25% EBITDAs and 18% to 20%” (13 Oct 2026, transcript)
  • FY27 EBITDA margin: “In FY27, we have said this earlier with all our meetings, we are expecting around 25% growth on revenue, and EBITDA margins will be historically in the same range that we have delivered over the past 2 years, where EBITDAs are what we are aiming to deliver is around 23% to 25% EBITDAs and 18% to 20%” (13 Oct 2026, transcript)
  • FY27 PAT margin: “In FY27, we have said this earlier with all our meetings, we are expecting around 25% growth on revenue, and EBITDA margins will be historically in the same range that we have delivered over the past 2 years, where EBITDAs are what we are aiming to deliver is around 23% to 25% EBITDAs and 18% to 20%” (13 Oct 2026, transcript)
AI read of the filing Glass Wall Systems Approves Q1 FY27 Results; Notes ₹332.06 Mn Tax Dispute and Director Appointment Watch
  • Completed IPO of 23,510,425 equity shares at ₹182 each, raising ₹600.00 Million in fresh issue and ₹3,678.90 Million via OFS; listed on September 16, 2026
  • Appointed Amit Jawahar Hemrajani as Additional Non-Executive Director for a 5-year term starting October 6, 2026
  • Maharashtra VAT and CST assessment demand of ₹312.13 Million and ₹19.93 Million quashed by MSTT challenged by the department in Bombay High Court on August 24, 2026
Full analysis →

Symbiotec Pharmalab Limited

SYMBIOTEC · Pharmaceuticals · Q1 FY27 · Consolidated · Filed
M Cap
₹7,442 Cr
P/E
—
PEG
—
Since results
+8.4%
  • Operating margin contracted 785 bps YoY
  • Behind management's FY27 revenue growth guidance of 20% (Q1 FY27 +7.5%)
  • Behind management's FY27 EBITDA growth guidance of 25% (Q1 FY27 -22.1%)
₹ CrYoYQoQ Jun 2026Mar 2026Jun 2025
Sales +7.5%-11.0% 218245203
Operating profit -22.1%-27.1% 45.262.058.0
OPM % -785 bps-459 bps 20.7%25.3%28.6%
Other income -88.7%— 0.30.03.0
Net profit? -53.1%-49.8% 14.128.030.0
PAT margin % -833 bps-498 bps 6.4%11.4%14.8%
EPS (₹) -95.2%-49.0% 2.244.3946.99

Quality of profit

Core 98%Other income & one-offs 2%

Pre-tax profit ₹17.5 Cr: core business ₹17.2 Cr, other income ₹0.3 Cr.

Core profit YoY: -59.1% · reported profit -53.1%

Management guidance ?

GuidedSo far
FY27 revenue growth 20% +7.5% Q1 FY27
behind
FY27 EBITDA growth 25% -22.1% Q1 FY27
behind
What management said
  • FY27 revenue growth: “Based on our current visibility and business outlook, we are definitely targeting 20% and 25% growth for this current fiscal year in our revenues and our EBITDA, respectively.” (28 Sep 2026, transcript)
  • FY27 EBITDA growth: “Based on our current visibility and business outlook, we are definitely targeting 20% and 25% growth for this current fiscal year in our revenues and our EBITDA, respectively.” (28 Sep 2026, transcript)
AI read of the filing Symbiotec Pharmalab Posts Q1 FY27 Results; Reports Standalone Loss of ₹156.90M Amid Recent Listing Negative
  • Standalone net loss stood at ₹156.90 million for Q1 FY27 compared to a net profit of ₹445.05 million in Q1 FY26
  • Basic and diluted EPS dropped to negative ₹2.73 and ₹2.71 respectively for the quarter ended June 30, 2026
  • Completed IPO of 17,786,442 equity shares at ₹988 per share, consisting of a ₹1,500.00 million fresh issue and ₹16,070.00 million OFS
Full analysis →

How to read this page

The numbers. Each card is one company's Q1 FY27 results as filed with NSE or BSE, read from the filing within hours of its release, in ₹ crore. We show the consolidated statement, or the standalone one when the consolidated figures are a copy of it or have no year-ago quarter to compare with. YoY compares with the same quarter a year earlier and QoQ with the quarter before (the previous half-year for companies that report every six months). A swing between profit and loss is described in words: a percentage across it would mislead.

Net profit. On a consolidated statement, net profit is the profit of the whole group for the quarter, before minority interest. A company's own headline, and the AI read of its filing, often quote the profit attributable to its shareholders instead, which is lower when subsidiaries are partly owned: Larsen & Toubro's Q1 FY27 group profit was ₹4,988 Cr, of which ₹4,123 Cr belonged to its shareholders. EPS is worked out on that attributable profit, so EPS and net profit need not grow at the same rate. On a standalone statement the two are the same.

Margins. Operating margin (OPM) is operating profit, before depreciation, interest and other income, as a share of sales; PAT margin is net profit as a share of sales. Their changes are in basis points (100 bps = 1 percentage point).

Quality of profit. Core profit is operating profit minus interest and depreciation: what the business itself earned before tax. The rest of pre-tax profit is other income (interest on cash, dividends, gains on investments) and exceptional or one-off items. We flag a quarter when that share is 25% or more, and when reported profit grew much faster than core profit. For banks we compare pre-provision profit with net profit, since a fall in provisions can lift profit without the business growing.

Against its own trend. We do not have analyst consensus estimates, and we do not make them up. Instead each company is measured against the path it was on: the same quarter last year, grown at the median of its last four year-on-year growth rates (held between −50% and +100%; at least two growth rates needed). Sales 5% or more above that, or net profit 10% or more above, is "above trend"; as far below is "below trend". It answers "was this quarter better or worse than the company's own recent run?", which consensus does not.

Cash and debt. Profit is an accounting figure; cash is harder to dress up. For each company we show its operating cash flow for the last financial year as a share of that year's net profit (flagged under 50%, or when it is negative despite a profit), and its borrowings at the latest balance sheet against the one six months earlier (flagged at a 25% move). Balance sheets come with the September and March results, the year's cash-flow statement with the March results and the half-year's (April to September) with the September results.

Management guidance. When a company files the transcript of its earnings call, we read what its management said to expect: revenue or profit growth, margins, capex and the like, for this financial year or part of it. A figure is kept only when the sentence that states it is found in the transcript, and you can read it under "What management said". Growth and margins are then set beside the actual so far: the year-to-date quarters against the same quarters a year earlier (so the first half is measured against a full-year figure). Within 1 percentage point of the range for growth, or 0.5 for margins, is "on track"; above it "ahead", below it "behind". A new figure for the same period is marked raised or cut against the one before. This is what management said, not a forecast of ours.

Working capital. Inventory, trade receivables and trade payables from the same balance sheets, each also as days of sales (the amount against the twelve months' sales to that date, times 365). Receivables or inventory that grow 25 points or more faster than sales between two balance sheets (and by at least 20%) are flagged: money tied up in customers and stock is profit not yet in cash. These lines are read from filings since the September 2026 results, so comparisons with an earlier balance sheet start with the March 2027 results for most companies.

Price since results. The latest close against the last close before the filing (a filing after 3:30 pm counts from the next session). It is a fact about the market's reaction, not advice.

Market cap groups. Large cap is the 100 largest companies by market value and mid cap the next 150 (SEBI's ranking); below that, small cap is ₹5,000 Cr or more, micro cap ₹500 Cr or more, nano cap below.

⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI